Zebrafish Functional Genomics by unknown
Interview: Stefan Schulte-Merker
Zebra®sh functional genomics
Artemis Pharmaceuticals have just announced a second saturation mutagenesis screen of the zebra®sh, Danio rerio. In this
interview with Stefan Schulte-Merker, who is Head of Fish Genetics at Artemis, we ®nd out more about the purpose of the
second screen and contrast it with the ®rst screen which was carried out in Christaine Nu Èsslein-Volhard laboratory and
which is now called `Tu Èbingen One'.
Stefan Schulte-Merker has been working with zebra®sh for over ten years and was involved in a number of genetic screens.
He was also part of a team that produced a ®rst-generation map of the `Goodfellow panel' of radiation hybrids, which was
intended to help in the cloning of the mutated genes. He is currently Head of Fish Genetics at Artemis Pharmaceuticals, in
Tu Èbingen, who are in the process of a second-round genetic screen, called `Tu Èbingen 2000'. Copyright # 2000 John Wiley
& Sons, Ltd.
CFG: How many genes of developmental importance
were identi®ed in the ®rst screen?
SS-M: It is hard to say how many genes the ®rst
screen has uncovered. This would require mapping
of all of the mutated genes, or checking of all
mutants for complementation. As an estimate, we
could use the fact that 4264 mutants were identi®ed
in Tu I (Tu Èbingen 1, the ®rst screen), with an allele
frequency of 2.4. Therefore, one could argue that
1777 genes were identi®ed (4264/2.4). However, the
number 2.4 stems from 894 mutants and might
therefore not be quite accurate.
CFG: Did you see any bias in the types of genes you
identi®ed, are they predominantly genes of known or
unknown function?
SS-M: Only a few of the genes have been cloned so
far, so it is hard to generalize about what types of
genes have been found, or the representation of
various pathways. So far, there is a strong bias
towards known genes, since candidate cloning has,
to date, been the primary method used to obtain the
genes. However, increasingly, groups are using
positional cloning and more novel genes are being
identi®ed. For example, the Zon lab recently found
a novel iron transporter gene by positional cloning
(Donovan et al., [2000]).
CFG: By what criteria did you decide that the ®rst
screen was not saturating?
SS-M: The trivial answer here is that you only ®nd
what you are looking for. The ®rst screen was
designed to uncover mutants affecting structures
that one could identify by looking at the live
embryos (with one exception, where ®xed embryos
were processed for staining retinotectal projections).
If you do not screen for, say, osteogenesis or blood
vessel formation, then you will not identify the
genes controlling those processes. So, whenever you
want to ®nd the essential genes in a process that
previously no-one has looked at, you basically have
to do a new screen. Given the complexity of the
early embryo and larva, there are many more genes
to be found. Even for those pathways studied, the
®rst screen has most likely not achieved saturation,
as can be deduced from the isolation of genes
involved in developmental pathways studies in Tu I,
but not detected by the screen, and from indepen-
dent projects by other groups. Also, there are
several genes that have been found in the Driever/
Fishman screens and not in the Tu Èbingen screen
and vice versa, indicating a lack of complete
coverage in either screen.
CFG: Do you have an estimate of how many of these
genes remain to be found?
SS-M: No, but it will be more than 1000 and
probably less than 5000. However, the number
depends on how you de®ne genes that are impor-
tant for early embryogenesis. One indication could
be taken from the allele frequency of 2.4 that we
observe, in experiments with C. elegans and
Drosophila, it has been shown that an allele
Yeast
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Copyright # 2000 John Wiley & Sons, Ltd.frequency of between 4 and 5 is required to achieve
saturation, so we can infer that we probably missed
our target by a factor of 2.
CFG: Can you give some examples of the types/roles
of genes you found in the ®rst screen? Are the genes
you found highly conserved across other species?
SS-M: The number of types of mutants from the
®rst screen is very high, and the only good way to
get an impression is to look at Development 123:
1±481. All mutants are described there. One group
of mutants that has been characterized particularly
well is mutants affecting dorsoventral patterning in
the early embryo. Here, many of the mutants have
been cloned, and it turns out that genes within the
BMP pathway have been found (BMP2 and BMP7,
tolloid, chordino). These genes, and what's more
important their function, have been conserved
though evolution. Another example is the group of
mutants affecting haematopoiesis. Here, genes have
been identi®ed that were known from humans
(globin, NRAMP2, ALAS), but there were also
genes identi®ed that scientists knew had to exist,
but which had not been uncovered. They were
identi®ed through cloning mutant genes that came
out of the screen.
CFG: What are the major differences between the
two screens? For example, how will the phenotypic
screens differ?
SS-M: We have learned lessons from the ®rst
screen, even though it has to be said that there were
no major shortcomings in the ®rst screen. During
Tu I, everybody screened for all phenotypes, while
during Tu 2000, specialists will screen for only one
particular (or two at most) trait(s). This way, it is
easier to compare phenotypes (all heart phenotypes
are seen by the same person), and the experience
factor is higher, which means that subtle pheno-
types will also be detected. The second screen will
cover more genomes than the ®rst.
The screens being done now have mostly a
completely different focus. The ®rst screen was
used to look for genes involved in early patterning
of the embryo, whilst the second is aiming more at
later stages of organogenesis. Angiogenesis, chon-
drogenesis and osteogenesis are areas that have not
been covered in previous screens. The assays we are
using to look at these developmental pathways are
more complex, requiring staining of vasculature,
cartilage or bone prior to assessment of the ®sh. By
contrast, in the ®rst screen, with the exception of
the staining for assay of the retinotectal projections,
all the assays involved more straightforward obser-
vation of living embryos under the microscope. We
did consider other avenues, such as the use of
transgenic lines expressing genes that mark out
tissue types, but we are limited in the types of
screens we can apply; for example, the assays we
choose must be robust and high throughput.
We are also trying to ensure that there will be at
least some ability to look for multiple phenotypes
per gene. We are using a database to log results,
which should help to detect any correlations
between phenotypes.
CFG: Chemical mutagenesis is a random process and
each ®sh may harbour several mutations. Do you plan
to include steps to ensure that each phenotype is
caused by mutation in only one gene?
SS-M: Even though every ®sh harbours many
different mutations, it is easy to decide whether
you have a single hit or a double mutant because in
the former case 1/4 of the embryos display the
phenotype, while in double mutants only 1/16 gives
a phenotype. With the genome being spread over 25
chromosomes, it is easy to separate the mutations.
A possible problem could only come from linked
double mutants; however, the likelihood of two
neighbouring (linked) genes being mutated in the
same genome is very small and can be neglected.
In conclusion, I would like to say that I feel that
the future of zebra®sh genomics lies in this type of
genetic screen and the identi®cation of the under-
lying genes. This remains the most amenable and
rapid way of obtaining gene function and can also
be modi®ed to take in advances such as transgenic
lines with marked tissue types. I would also argue
that the zebra®sh is still the most ef®cient vertebrate
system for this approach.
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www.wiley.co.uk/genomics
The Genomics website at Wiley is a new and DYNAMIC resource for the genomics community,
offering FREE special feature articles and new information EACH MONTH.
Find out more about Comparative and Functional Genomics, and how to view all articles published
this year FREE OF CHARGE!
Visit the Library for hot books in Genomics, Bioinformatics, Molecular Genetics and more.
Click on Primary Research for information on all our up-to-the minute journals, including:
Genesis, Bioessays, Gene Function and Disease, and the Journal of Gene Medicine.
Let the Genomics website at Wiley be your guide to genomics-related web sites, manufacturers and
suppliers, and a calendar of conferences.
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